These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31785096)

  • 1. Identifying the variables that drive tamoxifen-independent CreERT2 recombination: Implications for microglial fate mapping and gene deletions.
    Van Hove H; Antunes ARP; De Vlaminck K; Scheyltjens I; Van Ginderachter JA; Movahedi K
    Eur J Immunol; 2020 Mar; 50(3):459-463. PubMed ID: 31785096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2.
    Hirrlinger PG; Scheller A; Braun C; Hirrlinger J; Kirchhoff F
    Glia; 2006 Jul; 54(1):11-20. PubMed ID: 16575885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.
    Hameyer D; Loonstra A; Eshkind L; Schmitt S; Antunes C; Groen A; Bindels E; Jonkers J; Krimpenfort P; Meuwissen R; Rijswijk L; Bex A; Berns A; Bockamp E
    Physiol Genomics; 2007 Sep; 31(1):32-41. PubMed ID: 17456738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refinement of inducible gene deletion in embryos of pregnant mice.
    Savery D; Maniou E; Culshaw LH; Greene NDE; Copp AJ; Galea GL
    Birth Defects Res; 2020 Jan; 112(2):196-204. PubMed ID: 31793758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse.
    Lau J; Minett MS; Zhao J; Dennehy U; Wang F; Wood JN; Bogdanov YD
    Mol Pain; 2011 Dec; 7():100. PubMed ID: 22188729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A powerful transgenic tool for fate mapping and functional analysis of newly generated neurons.
    Zhang J; Giesert F; Kloos K; Vogt Weisenhorn DM; Aigner L; Wurst W; Couillard-Despres S
    BMC Neurosci; 2010 Dec; 11():158. PubMed ID: 21194452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of the strengths and potential caveats of the microglial inducible CreER mouse models.
    Bedolla AM; McKinsey GL; Ware K; Santander N; Arnold TD; Luo Y
    Cell Rep; 2024 Jan; 43(1):113660. PubMed ID: 38217856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tmem119-EGFP and Tmem119-CreERT2 Transgenic Mice for Labeling and Manipulating Microglia.
    Kaiser T; Feng G
    eNeuro; 2019; 6(4):. PubMed ID: 31371457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic Targeting of
    Kaiser T; Dattero J; Li L; Chen M; Jiang M; Harrahill A; Butovsky O; Feng G
    eNeuro; 2024 Jul; 11(7):. PubMed ID: 38926085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium.
    Monvoisin A; Alva JA; Hofmann JJ; Zovein AC; Lane TF; Iruela-Arispe ML
    Dev Dyn; 2006 Dec; 235(12):3413-22. PubMed ID: 17072878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cx3cr1
    Lee Y; Lee JW; Nam H; Yu SW
    Mol Brain; 2020 Jun; 13(1):88. PubMed ID: 32513210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gcg
    Shiota C; Prasadan K; Guo P; Fusco J; Xiao X; Gittes GK
    Diabetologia; 2017 Dec; 60(12):2399-2408. PubMed ID: 28884202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible gene manipulations in brain serotonergic neurons of transgenic rats.
    Weber T; Schönig K; Tews B; Bartsch D
    PLoS One; 2011; 6(11):e28283. PubMed ID: 22140568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perinatal induction of Cre recombination with tamoxifen.
    Lizen B; Claus M; Jeannotte L; Rijli FM; Gofflot F
    Transgenic Res; 2015 Dec; 24(6):1065-77. PubMed ID: 26395370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warning regarding hematological toxicity of tamoxifen activated CreERT2 in young Rosa26CreERT2 mice.
    Rossi M; Salomon A; Chaumontel N; Molet J; Bailly S; Tillet E; Bouvard C
    Sci Rep; 2023 Apr; 13(1):5976. PubMed ID: 37045870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generating endogenous Myh11-driven Cre mice for sex-independent gene deletion in smooth muscle cells.
    Zhao Y; Zhao G; Chang Z; Zhu T; Zhao Y; Lu H; Xue C; Saunders TL; Guo Y; Chang L; Chen YE; Zhang J
    JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37289544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Split-CreERT2: temporal control of DNA recombination mediated by split-Cre protein fragment complementation.
    Hirrlinger J; Requardt RP; Winkler U; Wilhelm F; Schulze C; Hirrlinger PG
    PLoS One; 2009 Dec; 4(12):e8354. PubMed ID: 20016782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic inducible fate mapping in adult mice using tamoxifen-dependent Cre recombinases.
    Feil S; Krauss J; Thunemann M; Feil R
    Methods Mol Biol; 2014; 1194():113-39. PubMed ID: 25064100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Adult Vestibular Organs in 11 CreER Mouse Lines.
    Stone JS; Wisner SR; Bucks SA; Mellado Lagarde MM; Cox BC
    J Assoc Res Otolaryngol; 2018 Aug; 19(4):381-399. PubMed ID: 29869046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Tissue-Specific Recombination in a Pdgfrα-CreERT2 Transgenic Mouse Line.
    O'Rourke M; Cullen CL; Auderset L; Pitman KA; Achatz D; Gasperini R; Young KM
    PLoS One; 2016; 11(9):e0162858. PubMed ID: 27626928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.